HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reaffirmed a Buy rating on Travere Therapeutics (NASDAQ:TVTX) and increased the price target from $18 to $20.
December 15, 2023 | 6:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Travere Therapeutics' Buy rating is maintained by HC Wainwright & Co., with a raised price target from $18 to $20, indicating a positive outlook.
The reaffirmation of a Buy rating and an increase in the price target typically signal analyst confidence in the company's future performance, which can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100